Detecting kidney cancer recurrence after treatment
Multi-modality detection of RCC Recurrence Post Ablation
This study is looking at how well a special type of ultrasound can help find kidney cancer returning after treatment, and it's for patients who have had early-stage kidney cancer and want a safer imaging option.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10993181 on NIH RePORTER |
What this research studies
This research focuses on improving the detection of kidney cancer recurrence following localized ablation, a treatment for early-stage renal cell carcinoma. It aims to evaluate the effectiveness of contrast-enhanced ultrasound (CEUS) compared to traditional imaging methods like contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (CEMRI). The study will involve monitoring patients post-ablation to assess the sensitivity and specificity of CEUS in identifying any signs of cancer recurrence. By utilizing CEUS, the research seeks to provide a safer and more accurate imaging alternative for patients who may have contraindications to other imaging modalities.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with early-stage renal cell carcinoma who have undergone localized ablation treatment.
Not a fit: Patients with advanced renal cell carcinoma or those who have not undergone ablation treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and safer methods for monitoring kidney cancer recurrence, improving patient outcomes.
How similar studies have performed: Previous pilot studies have shown promising results for using contrast-enhanced ultrasound in monitoring kidney cancer recurrence, indicating potential for success in this approach.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Eisenbrey, John — Thomas Jefferson University
- Study coordinator: Eisenbrey, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.